Sees FY24 gross margin to be approximately 50% to 53% of revenues; selling, general and administrative costs to be approximately $630M to $650M; research and development costs to be $325M to $345M, and net cash consumption to be $50M to $75M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera announces next phase of CareDx patent infringement litigation
- Canaccord bullish on Natera growth potential as Medicare extends coverage
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
